- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07811778
Transcutaneous Electrical Acupoint Stimulation Combined With Exposure and Response Prevention in the Treatment of Patients With Obsessive-Compulsive Disorder: A Randomized Controlled Trial
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Jue Chen
- Telefonnummer: +8618017311203
- E-post: chenjue2088@163.com
Studieorter
-
-
-
Shanghai, Kina
- Shanghai Mental Health
-
Kontakt:
- Jue Chen
- Telefonnummer: +8618017311203
- E-post: chenjue2088@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age: 18 - 50 years old, gender not restricted;
- Meets the diagnostic criteria for obsessive-compulsive disorder as per the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
- Yale-Brown Obsessive Compulsive Scale score ≥ 16 points;
- Has never taken medication or is currently taking medication with a stable dosage for 8 weeks or more;
- Has a junior high school education or above;
- Has signed the informed consent form.
Exclusion Criteria:
- Meets the diagnosis criteria in DSM-5 except for obsessive-compulsive disorder (excluding obsessive-compulsive personality disorder);
- Has severe obsessive symptoms that prevent the patient from completing the required assessment tests;
- Has a history of brain injury or surgery, or has an implanted cardiac pacemaker or other metal device in the body;
- Pregnant or planning to become pregnant women, breastfeeding women;
- Substance abusers within the past year;
- Have severe negative thoughts or a high risk of suicide;
- Other conditions deemed unsuitable for inclusion by the researchers.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ERP+TEAS treatment group
ERP+TEAS treatment group has 45 OCD patients.Each patient receives 16 sessions of ERP for 50 minutes.
TEAS procedure is truly exciting and is carried out simultaneously with ERP.
The targeted stimulation points are the bilateral Neiguan acupoints.
|
The first one is to establish the therapeutic relationship, mainly aimed at discussing the changes that the upcoming treatment can bring to the patient, helping the patient understand that their obsessive-compulsive symptoms are mainly due to their dysfunctional evaluation system and helping them understand the reasons for the gradual increase in their obsessive behaviors.
Normalization of anxiety and the analysis of the pros and cons of anxiety lay the groundwork for the next exposure therapy.
The therapist also needs to help the patient understand and accept the next TEAS synchronous ERP treatment.
In the last treatment, the therapist should summarize the treatment process with the patient.
In addition, the therapist needs to understand the patient's feedback on the treatment, consolidate the achieved treatment effects, and jointly discuss the prevention of recurrence with the patient.
The acupoints stimulated are bilateral Neiguan points.
The stimulation positioning is based on the "National Standard of the People's Republic of China · Acupoint Names and Locations" [GB/T 12346-2021] (2021).
The stimulation frequency is 50Hz, and the pulse width can change with the frequency.
The pulse amplitude (0-100 mA) is titrated to a "strong but comfortable" sensation level.
The ERP treatment lasts for 8 weeks, twice a week, for a total of 16 sessions, all of which are TEAS synchronized with ERP treatment.
Each treatment lasts for 50 minutes, with the first 20 minutes being the therapist's theoretical explanation, and the last 30 minutes being exposure practice.
The TEAS stimulation starts simultaneously with the patient's exposure practice, and the stimulation duration is also 30 minutes.
|
|
Sham Comparator: ERP+sham-stimulation group
ERP+sham-stimulation group has 45 patients.Each patient receives 16 sessions of ERP for 50 minutes.
TEAS intervention uses sham coils and is carried out simultaneously with ERP.
The targeted stimulation points are the bilateral Neiguan acupoints.
|
The first one is to establish the therapeutic relationship, mainly aimed at discussing the changes that the upcoming treatment can bring to the patient, helping the patient understand that their obsessive-compulsive symptoms are mainly due to their dysfunctional evaluation system and helping them understand the reasons for the gradual increase in their obsessive behaviors.
Normalization of anxiety and the analysis of the pros and cons of anxiety lay the groundwork for the next exposure therapy.
The therapist also needs to help the patient understand and accept the next TEAS synchronous ERP treatment.
In the last treatment, the therapist should summarize the treatment process with the patient.
In addition, the therapist needs to understand the patient's feedback on the treatment, consolidate the achieved treatment effects, and jointly discuss the prevention of recurrence with the patient.
A transient placebo-tens simulation stimulation was adopted.
A bonding electrode pad was placed 1 cm radially from the Neiguan acupoint.
The stimulation intensity was adjusted to the minimum sensory threshold for 30 seconds, then gradually reduced over the next 15 seconds, making the stimulation active for a total of 45 seconds.
This ensured that no current was transmitted to the electrode pad while maintaining the blinding condition.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The reduction rate of the Yale Brown Depression Scale
Tidsram: week 0(baseline), week 8(post-intervention), week12 (follow-up)
|
Calculation: Baseline YBCOS total score - Follow-up YBOCS total score / Baseline YBCOS total score.A deduction rate of 35% or higher is considered valid.
|
week 0(baseline), week 8(post-intervention), week12 (follow-up)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
The reduction rate of the BDI-II
Tidsram: week 0(baseline), week 8(post-intervention), week12(follow-up)
|
BDI-II:It consists of 21 items, used to assess the severity of each depressive symptom. Each item is divided into four levels ranging from 0 to 3. The total score of the scale is the sum of the scores of the 21 items. The BDI-II is one of the most widely used self-rating depression scales at present. The Chinese version was introduced by this research group and its reliability and validity were evaluated. Calculation: Baseline BDI total score - Follow-up BDI total score / Baseline BDI total score. A reduction rate of 50% or higher is considered valid. |
week 0(baseline), week 8(post-intervention), week12(follow-up)
|
|
The reduction rate of BAI
Tidsram: Time Frame: week 0(baseline), week 8(post-intervention), week12(follow-up)
|
BAI:It consists of 21 items, each of which is divided into 0-3 levels, and is used for self-assessment of individual anxiety symptoms. The total score is the sum of the scores of each item, and the possible score range is 0 to 63 points. The higher the score, the more severe the anxiety symptoms. This scale has good internal consistency and test-retest reliability. Its Chinese version has similar reliability and validity to the original version. Calculation: Baseline BAI total score - Follow-up BAI total score / Baseline BAI total score. A reduction rate of 50% or higher is considered valid. |
Time Frame: week 0(baseline), week 8(post-intervention), week12(follow-up)
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Jue Chen, Shanghai Mental Health Center
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2026-OCD67
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .